Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Namuscla 167 mg hard capsules
DRUG
2 trials
Sponsors
Lupin Europe GmbH
, Lupin Atlantis Holdings S.A.
Conditions
Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM
Non-Dystrophic Myotonias (NDM)
type 1 or type 2)
Phase 3
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)
Recruiting
CTIS2024-514970-27-00
Lupin Atlantis Holdings S.A.
Non-Dystrophic Myotonias (NDM)
Start: 2025-09-03
Target: 20
Updated: 2025-09-30
Phase 4
Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed MEX-NM-301.
Not yet recruiting
CTIS2024-513484-89-00
Lupin Europe GmbH
Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)
Target: 12
Updated: 2025-04-14